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Abstract. Occult macular dystrophy (OMD) is an inherited 
macular disease characterized by progressive visual decline 
with the absence of visible retinal abnormalities. Typical 
alterations of the retinal structure are detectable by spectral 
domain optical coherence tomography (SD‑OCT). Mutations 
in the RP1L1 gene have been identified to be responsible for 
the disease in Asian subjects. The present study assessed the 
role of mutations in the RP1L1 gene in an Italian family with 
OMD. One patient with OMD and five related subjects (two 
male offspring affected by progressive visual decline and 
three asymptomatic siblings of the patient) were subjected to 
complete ophthalmological examination. SD‑OCT was also 
performed. All subjects were screened for OMD‑associated 
genetic mutations in the RP1L1 gene. The OMD patient and 
the two symptomatic offspring presented with a reduced 
best‑corrected visual acuity. Although no fundus abnormali‑
ties were observed, SD‑OCT examination showed that the 
external limiting membrane and the inner segment/outer 
segment band were not clearly identifiable and a focal disrup‑
tion of the photoreceptor layer was present. The degree of 
photoreceptor alterations was correlated with the severity of 
visual impairment. Clinical and tomographic results in the 
three asymptomatic relatives were normal. A p.Arg45Trp 
mutation in the RP1L1 gene was identified in the OMD 
patient, in the two symptomatic offspring and also in two of 
the asymptomatic siblings of the patient. The identification 
of RP1L1 mutations in subjects with OMD may improve the 
accuracy of diagnosis of this rare condition and may aid in 
enhancing the efficacy of genetic counseling.
Introduction
Occult macular dystrophy (OMD) is an inherited macular 
disease characterized by progressive visual decline with the 
absence of visible fundus abnormalities (1). The condition 
was first recognized in 1989 as an autosomal dominant trait, 
although sporadic cases have also been reported (1‑3). In 
patients with OMD, the full‑field electroretinogram (ERG) is 
normal; however, the focal macular ERG and multifocal ERG 
(mfERG) of the macular area are affected, revealing localized 
dysfunction of the photoreceptors (1,4,5).
Despite normal fundus appearance, spectral domain optical 
coherence tomography (SD‑OCT) reveals various degrees 
of macular changes in OMD patients. Typical OCT features 
of OMD patients are a disruption of the inner segment/outer 
segment (IS/OS) junction and the disappearance of the cone 
outer segment tip (COST) line (6). Subtle changes of normal 
macular reflectance may also be noted in infrared reflectance 
images of the fundus (7).
Mutations in the retinitis pigmentosa 1‑like 1 (RP1L1) gene 
have been identified in four Japanese families with OMD (8). 
To date, the association between OMD and RP1L1 mutations 
has mostly been reported in Asian subjects (7‑10). Only two 
studies on Caucasian subjects with OMD are available, of 
which only one included an analysis for RP1L1 gene muta‑
tions (11,12). The present study was the first to report on an 
Italian family with typical OMD and a RP1L1 mutation.
Materials and methods
Patient examination and clinical data collection. In 2013, 
a Caucasian family comprising several members diagnosed 
with OMD was assessed. In accordance with the Declaration 
of Helsinki, all patients provided written informed consent 
to full ophthalmological examination and genetic testing 
for OMD mutations. All subjects were evaluated by expert 
ophthalmologists at the Opthalmology Associates in Padova 
(Italy). Each subject underwent complete ophthalmological 
assessment, including best‑corrected visual acuity (BCVA), 
slit‑lamp examination, IOP measurement and ophthalmos‑
copy. Color vision testing was performed using Ishihara 
pseudochromatic plates. High‑resolution macular scans were 
obtained by SD‑OCT (3D‑OCT 2000; Topcon, GB Ltd., 
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Newbury, UK). The medical records of the subjects were also 
thoroughly analyzed.
Genetic testing. Genetic testing was performed at the Research 
and Innovation Laboratories Srl (Padova, Italy). DNA extrac‑
tion was performed from peripheral blood using the Qiagen 
Biorobot blood extraction kit (Qiagen, Hilden, Germany) 
according to maufacturer's instructions. 100 ng DNA were 
amplified by standard polymerase chain reaction (PCR) 
procedures with the PCR mixture containing 2.5 µl 10X 
concentrated PCR buffer (Solis Biodyne, Tartu, Estonia), 0.7 µl 
50 mM MgCl2 (Solis Biodyne), 0.75 µl 10 mM deoxyribo‑
nucleotide triphosphates (Solis Biodyne), 2.5 µl S solution (Solis 
Biodyne), 0.3 µl 100 µM forward and reverse primer (IDT, 
Coralville, IA, USA; primer sequences are listed in Table I) 
and 0.5 µl 5 U/µl Hot Start DNA Polymerase (Solis Biodyne). 
Termocycling consisted in 1 cycle of enzyme activation (15 min 
at 95˚C) followed by 35 cycles of DNA amplification (45 sec at 
95˚C, 45 sec at 59˚C and 1 min at 72˚C). PCR products were 
then separated by agarose gel electrophoresis (1.5% agarose 
gel in tris‑borate‑ethylenediaminetetraacetate; Sigma‑Aldrich, 
St. Louis, MO, USA) and purified by Invisorb spin columns 
(Invitek, Hayward, CA, USA). PCR‑purified products were 
re‑amplified with terminated nuclotides employing Big Dye 
Terminator v3.1 (Applied Biosystems; Thermo Fisher Scientific, 
Waltham, MA, USA). Sequencing analysis was performed using 
an ABI Prism 3100 Avant automated sequencer (Thermo Fisher 
Scientific) equipped with 36‑cm capillary array filled with 
POP6 polymer (Thermo Fisher Scientific). Electropherograms 
were analyzed using Sequencing Analysis software (version 3.5; 
Applied Biosystems).
Results
Ophthalmological assessment. As illustrated in Fig. 1, the 
study included six members of an Italian family (four males 
and two females), among which three presented with OMD 
(subjects, II 1, III 1 and III 2).
The main patient (subject II 1) was a 67‑year‑old male. The 
BCVA was ʻcounting fingersʼ in both eyes (OU) without any 
detectable alteration of the anterior and posterior segment of 
the eye. The patient's medical records revealed a progressive 
visual decline beginning at age 59. The results of the slit‑lamp 
examination as well as intraocular pressure and fundus appear‑
ance were normal. The results of the color vision test was also 
normal until the BCVA reached 0.3. Automated perimetry 
revealed a central relative scotoma in OU. Full‑field ERG 
was within normal limits, whereas multi‑focal ERG showed a 
reduction of the amplitudes in the central region. Clinical and 
instrumental findings were matched the diagnosis of OMD.
SD‑OCT was then performed; macular scans showed that 
in the foveal region, the external limiting membrane (ELM) 
and the inner segment‑outer segment (IS/OS) line were not 
sharply identifiable from each other. In addition, the cone 
outer segment tip (COST) line was disrupted (Fig. 2). A mild 
hyperreflectivity of the internal limiting membrane was also 
present, and central retinal thickness was reduced.
The second patient (subject III 1) was a 38‑year‑old male. 
The BCVA was 0.2 in OU, and no ocular abnormalities were 
detected by slit‑lamp and fundus examination. The patient's 
medical records reported progressive visual decline, associ‑
Figure 1. Pedigree of a caucasian family with OMD. The identification num‑
bers of the study subjects are stated below the symbols. Circles, females; 
squares, males; OMD, occult macular dystrophy.
Table I. Primer sequences.
Primer name Primer sequence Mutations
RP1L1 1199 Fw GGGCTCTCATAAGTTCTTGAATCAG Ser1199Cys
RP1L1 1199 Rv GCAGATCATGAGGGCGCT
RP1L1 960 Fw AAGGAGAAGCAGTGCCAGCC Trp960Arg
RP1L1 960 Rv TGCTGTCCCGCCTGAGC
RP1L1 45 Fw AAGAGACAGGAAATGCCAATCC Arg45Trp
RP1L1 45 Rv TCTTATCAGAGCAGAGGTAGCAGC
RP1L1 2311 Fw CTTCACTGGCCCCCTGCT Gln2311Pro, Gln2311Glu
RP1L1 2311 Rv GCCCTCAGGTCAGTCTAGGAGAT
RP1L1 1425 Fw CGTGTGCTCTTGGCCCAT Asp1425Glu, Asp1425His
RP1L1 1425 Rv TGCAGTTAGAGGAAGTTAAAGAAGGG
 
FW, forward; Rv, reverse.
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ated with photophobia, starting at age 15. Color vision testing 
showed a red‑green defect and automated perimetry revealed 
a central relative scotoma in OU. SD‑OCT results regarding 
the ELM, the IS/OS line and the COST line were similar to 
those observed in subject II 1; however, the affected area was 
smaller (Fig. 2).
Subject III 2 was a 32 year‑old male. The subject's BCVA 
was 0.6 in OU, with no evidence of any changes in ocular 
morphology. Color vision testing showed normal results. The 
patient presented with a slow, progressive decline of visual 
acuity since age 28. The SD‑OCT findings were comparable 
to those in subjects II 1 and III 1, although the area involved 
was minimal (Fig. 2).
In addition, clinical assessment of three clinically asymp‑
tomatic siblings of subject II 1 (II 2, II 3 and II 4, a 51 year‑old 
male, a 56 year‑old female and a 66 year‑old female, respectively) 
was performed (Fig. 1). All three subjects had a BCVA of 1.0 in 
OU and normal results of the ophthalmological examination. 
SD‑OCT revealed that the retinal layers were normal.
Analysis of RP1L1 mutations. Subject II 1 was screened for the 
following targeted mutations in the RP1L1 gene: Ser1199Cys, 
Trp960Arg, Arg45Trp, Gln2311Pro, Gln2311Glu, Asp1425His 
and Asp1425Glu. Of these, the Arg45Trp mutation, which 
was reported by Akahori et al (8) to be associated with auto‑
somal‑dominant OMD, was identified in subject II (Fig. 3A). 
As Arg45Trp was previously found to be correlated with 
occult macular dystrophy, subjects III 1, III 2, II 2, II 3 and 
II 4 were also screened for this specific mutation. As expected 
due to their clinical diagnosis, subjects III 1 and III 2 were 
also carriers of the Arg45Trp mutation (Fig. 3B and C). While 
subjects II 2 and II 4 were also carriers of the Arg45Trp muta‑
tion, they displayed no clinical symptoms of OMD (Fig. 3D 
and F). The Arg45Trp mutation was not present in subject II3 
(Fig. 3E). Therefore, in the study population, the Arg45Trp 
mutation was present in 3/5 subjects (60%).
Discussion
The prevalence of occult macular dystrophy (OMD) appears 
to be elevated Asian populations, as the majority of available 
studies have been performed in Japanese or Korean popula‑
tions (1,4‑10). Only two studies on Caucasian subjects with 
OMD are available, of which only one included an analysis for 
RP1L1 gene mutations (11,12).
OMD is an autosomal inherited condition, although 
sporadic cases have also been reported. RP1L1 was identified 
as a gene responsible for the disease in 2010 (8). RP1L1 is 
located on chromosome 8p and originates from the common 
ancestor gene retinitis pigmentosa 1 (RP1) on chromosome 8. 
RP1L1 shares 35% amino acid identity with RP1, a gene 
responsible for 51% of autosomal dominant retinitis pigmen‑
tosa cases worldwide (8,11). RP1 is responsible for 5‑10% of 
autosomal dominant retinitis pigmentosa cases worldwide (11). 
Although RP1L1 shares 35% amino acid identity with RP1, 
RP1L1 mutations are not associated with retinitis pigmentosa.
Immunohistochemical studies on RP1L1 in retinal sections 
of cynomolgus monkeys showed that the gene is expressed in 
rods as well as cones (8). Although the function of RP1L1 
remains to be fully elucidated, it probably cooperates with 
RP1 to assemble and stabilize the microtubules of the photo‑
receptor axonemes (13).
While the link between OMD and RP1L1 mutations has 
been reported in Asian and north European pedigrees, the 
present study was the first to demonstrate that an RP1L1 
mutation is likely to be associated with OMD in an Italian 
family. The substitution mutation p.Arg45Trp was identified 
in a patient who met the diagnostic criteria for OMD, as well 
as in the two symptomatic male offspring of the patient and 
also in two clinically asymptomatic siblings of the patient. 
Tsunoda et al (10), who reported on a Japanese family carrying 
the p.Arg45Trp mutation, found that the age of onset of OMD 
ranged from 6‑50 years. It is often difficult to establish the true 
Figure 2. Spectral domain optical coherence tomography scans (left column, horizontal; right column, vertical) of right eye of subjects II 1, III 1 and III 2. 
In all three patients, the external limiting membrane and the inner segment/outer segment line appeared blurred, and the cone outer segment tip line was 
disrupted. Arrowheads indicate the areas affected by morphological changes to the outer retinal layers. The extent of macular alteration was correlated with 
the best‑corrected visual acuity (counting fingers in subject II 1, 0.2 in subject III 1 and 0.6 in subject III 2).
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age of onset of the disease, as certain patients with OMD have 
normal visual acuity and no subjective visual disturbance until 
the disease progresses to a more advanced stage (10). In the 
pedigree assessed in the present study, the age of first presenta‑
tion of visual symptoms ranged from 15 years for subject III 1 
to 59 years of age for subject II 1. The onset of progressive 
BCVA reduction reported by Tsunoda et al (10) ranged from 
6‑50 years of age. Similarly, in the present study, the onset of 
progressive BCVA reduction varied. Similarly, in the present 
study, the rate of the progression of the visual decline varied. 
Subject II 1 became legally blind over a period of eight years, 
while subject III 1 showed a slower reduction of BCVA, which 
decreased to 0.2 over a period of 23 years. BCVA of the third 
proband decreased to 0.6 over three years; however, the time 
of observation was too short to predict the rate of progression. 
OMD has been reported to be a slowly progressing disease, 
while the visual function usually became stationary when the 
final visual acuity reached a value of 0.1‑0.2 (8,10). However, 
the BCVA of Subject II 1 deteriorated to counting fingers in 
OU.
The diagnosis of OMD is challenging, as no detectable 
fundus abnormalities are present at advanced stages. Despite 
normal fundus appearance, SD‑OCT is able to identify a 
number of alterations in the outer retinal layers in the majority 
of OMD patients. Tomographic features of OMD include 
central retinal thinning, blurring of the ELM and IS/OS band 
as well as disruption of the COST line, whereas the RPE band 
is always preserved (6‑7,10). All of these characteristics were 
observed in the OMD patients of the present study. It has also 
been reported that the degree of these alterations worsens 
over time and correlates with visual impairment. In spite of 
the small number of patients included in the present study, it 
was indicated that a better visual acuity is correlated with less 
extensive macular alterations.
Thorough analysis of SD‑OCT scans of asymptomatic 
subjects II 2, II 3 and II 4 revealed that no major or minimal alter‑
ations of the outer retinal layers were present. Tsunoda et al (10) 
reported that even though certain OMD patients showed a good 
BCVA or did not complain about any visual symptoms, the 
mfERG revealed the presence of a macular dysfunction.
Figure 3. Arg45Trp electropherograms for the study subjects. (A) Subject II 1; (B) subject III 1; (C) subject III 2; (D) subject II 2; (E) subject II 4; (F) subject II 3.
  A   B
  C   D
  E   F
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In conclusion, the present study was the first to demon‑
strate the occurrence of the p.Arg45Trp mutation in the 
RP1L1 gene in an Italian pedigree including OMD patients. 
The RP1L1 Arg45Trp mutation, at least in the cohort of 
the present study, appeared to have incomplete penetrance. 
Davidson et al (12) suggested the Arg45Trp mutation as a risk 
factor for OMD rather than a causative mutation. However, 
the reason for the incomplete penetrance displayed by 
individuals possessing the OMD‑associated RP1L1 variant 
p.Arg45Trp remains elusive. A digenic or oligogenic model 
involving other genes requires further investigation. In the 
present study, the first of South‑European origin, a disease 
penetrance of 60% was presented; this is higher than that 
observed by Davidson et al (12) (38%), and more comparable 
with a study on Asian subjects by Akahori et al (8) (identified 
85% penetrance). In addition Davidson et al (12) concluded 
that the Arg45Trp mutation is a risk factor, not a causative 
mutation, for OMD, based on the observation that none of 
their patients had familial history of autosomal‑dominant 
maculopathy. In the current study, a Caucasian father and 
his two sons are described who presented with OMD, thus 
supporting the role of the Arg45TRp mutation in the cause 
of the disease in non‑Asian subjects. Of note, as the age of 
onset for OMD is variable, clinical diagnosis of OMD is 
challenging and healthy carriers of the Arg45Trp mutation 
should be considered to be at risk, and periodic clinical 
screening for OMD is recommended.
Based on previous studies and the observations of the 
present study, it is indicated that screening for mutations 
in the RP1L1 gene associated with progressive reduction of 
BCVA and typical OCT per se may be sufficient to confirm 
the diagnosis of OMD. Under these circumstances, mfERG 
is not necessary (as in subjects III 1 and III 2). However, 
when visual symptoms or fundus abnormalities are absent, 
but genetic testing is positive, mfERG may be the only 
test with the capability of early detection of an impending 
macular dysfunction.
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